乳腺原发性神经内分泌癌：不断变化的模式
Primary Neuroendocrine Carcinoma of Breast: Changing Paradigm.
作者信息
Chakraborty Arnab
机构信息
Surgical Oncology & Breast Services, The Mission Hospital, Durgapur, West Bengal 713212 India.
出版信息
Indian J Surg Oncol. 2025 Feb;16(1):60-63. doi: 10.1007/s13193-024-02026-5. Epub 2024 Jul 18.
Abstract
Neuroendocrine carcinomas are one of the most rare malignancies of the breast. Theoretically they can arise from any organ of the body, but incidence in breast is very rare. Due to the ever-changing definition of the disease, no specific therapeutic guideline is available in current literature. Currently WHO defines neuroendocrine carcinoma of breast as malignant lesions that expresses > 90% of neuroendocrine markers like synaptophysin, chromogranin A with characteristic histopathology features with exclusion of solid papillary carcinoma, and hypercellular-type mucinous carcinoma.
摘要
神经内分泌癌是乳腺最罕见的恶性肿瘤之一。理论上，它们可起源于身体的任何器官，但在乳腺中的发病率非常低。由于该疾病的定义不断变化，目前的文献中没有具体的治疗指南。目前，世界卫生组织将乳腺神经内分泌癌定义为表达超过90%神经内分泌标志物（如突触素、嗜铬粒蛋白A）的恶性病变，具有特征性的组织病理学特征，不包括实性乳头状癌和高细胞型黏液癌。
相似文献
1
Primary Neuroendocrine Carcinoma of Breast: Changing Paradigm.乳腺原发性神经内分泌癌：不断变化的模式
Indian J Surg Oncol. 2025 Feb;16(1):60-63. doi: 10.1007/s13193-024-02026-5. Epub 2024 Jul 18.
2
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物：网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
3
Antidepressants for chronic non-cancer pain in children and adolescents.用于治疗儿童和青少年慢性非癌性疼痛的抗抑郁药。
Cochrane Database Syst Rev. 2017 Aug 5;8(8):CD012535. doi: 10.1002/14651858.CD012535.pub2.
4
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中，如果患者出现以下症状和体征，可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
Interventions for fertility preservation in women with cancer undergoing chemotherapy.对接受化疗的癌症女性进行生育力保存的干预措施。
Cochrane Database Syst Rev. 2025 Jun 19;6:CD012891. doi: 10.1002/14651858.CD012891.pub2.
7
[Neuroendocrine tumors of the breast: Myth or reality? A systematic review].[乳腺神经内分泌肿瘤：神话还是现实？一项系统综述]
Bull Cancer. 2018 Apr;105(4):431-439. doi: 10.1016/j.bulcan.2018.01.013. Epub 2018 Mar 19.
8
Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome.用于控制经前综合征症状的含雌激素非避孕制剂。
Cochrane Database Syst Rev. 2017 Mar 3;3(3):CD010503. doi: 10.1002/14651858.CD010503.pub2.
9
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.用于儿童和青少年慢性非癌性疼痛的非甾体抗炎药（NSAIDs）
Cochrane Database Syst Rev. 2017 Aug 2;8(8):CD012537. doi: 10.1002/14651858.CD012537.pub2.
10
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.仑伐替尼联合帕博利珠单抗治疗未经治疗的晚期肾细胞癌：系统评价和成本效果分析。
Health Technol Assess. 2024 Aug;28(49):1-190. doi: 10.3310/TRRM4238.
本文引用的文献
1
Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives.乳腺原发性神经内分泌肿瘤：当前认识与未来展望
Front Oncol. 2022 May 25;12:848485. doi: 10.3389/fonc.2022.848485. eCollection 2022.
2
Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast.验证乳腺神经内分泌肿瘤提出的统一分类框架的预后意义。
Breast Cancer Res Treat. 2021 Apr;186(2):403-415. doi: 10.1007/s10549-021-06099-6. Epub 2021 Feb 2.
3
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.替莫唑胺单药或联合卡培他滨治疗转移性神经内分泌肿瘤：一项“真实世界”数据分析。
Neuroendocrinology. 2021;111(9):895-906. doi: 10.1159/000513218. Epub 2020 Nov 20.
4
The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.浸润性乳腺癌中神经内分泌特征的临床意义。
Oncologist. 2020 Sep;25(9):e1318-e1329. doi: 10.1634/theoncologist.2020-0081. Epub 2020 Jun 16.
5
177Lu-DOTATOC Peptide Receptor Radionuclide Therapy in a Patient With Neuroendocrine Breast Carcinoma and Breast Invasive Ductal Carcinoma.177Lu-DOTATOC 肽受体放射性核素治疗神经内分泌乳腺癌和乳腺浸润性导管癌患者。
Clin Nucl Med. 2020 May;45(5):e232-e235. doi: 10.1097/RLU.0000000000003005.
6
The 2019 World Health Organization classification of tumours of the breast.《2019年世界卫生组织乳腺肿瘤分类》
Histopathology. 2020 Aug;77(2):181-185. doi: 10.1111/his.14091. Epub 2020 Jul 29.
7
Primary Neuroendocrine Breast Carcinoma in a 13-Year-Old Girl: Ultrasonography and Pathology Findings.一名13岁女孩的原发性神经内分泌乳腺癌：超声检查与病理结果
Case Rep Radiol. 2017;2017:7915806. doi: 10.1155/2017/7915806. Epub 2017 Sep 10.
8
Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.乳腺神经内分泌癌的综合临床和分子分析。
Mod Pathol. 2018 Jan;31(1):68-82. doi: 10.1038/modpathol.2017.107. Epub 2017 Sep 8.
9
Neuroendocrine carcinoma of the breast: a review of 126 cases in China.乳腺神经内分泌癌：中国126例病例回顾
Chin J Cancer. 2017 May 11;36(1):45. doi: 10.1186/s40880-017-0211-x.
10
Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.乳腺神经内分泌癌中的新突变：可能的治疗靶点。
Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):97-103. doi: 10.1097/PDM.0b013e3182a40fd1.
Zotero 插件